Product
Palivizumab
Name
Synagis
INN Name
palivizumab
FDA Approved
Yes
2 clinical trials
1 organization
2 indications
1 document
Indication
Respiratory Syncytial Virus InfectionIndication
Respiratory Syncytial Virus InfectionsClinical trial
A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV DiseaseStatus: Recruiting, Estimated PCD: 2025-06-28
Clinical trial
A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)Status: Completed, Estimated PCD: 2021-05-03
Document
DailyMed Label: Synagis
Organization
SWEDISH ORPHAN BIOVITRUM AB (PUBL)